United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of    —   paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms    —   paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of    —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets, usp are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets, usp should not be used in patients with recent myocardial infarction. (see boxed warnings .) use of flecainide acetate tablets, usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings .) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, usp favorably affects survival or the incidence of sudden death. flecainide acetate tablets are contraindicated in patients with pre existing second- or third-degree av block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of    —   paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms    —   paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of    —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets, usp are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets, usp should not be used in patients with recent myocardial infarction. (see boxed warnings .) use of flecainide acetate tablets, usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings .) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, usp favorably affects survival or the incidence of sudden death. flecainide acetate tablets are contraindicated in patients with preexisting second- or third-degree av block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate is indicated for the prevention of: flecainide acetate is also indicated for the prevention of: use of flecainide acetate for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate should not be used in patients with recent myocardial infarction. (see boxed warnings.) use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings.) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or t

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 100 mg - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets usp are also indicated for the prevention of: - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide is indicated for the prevention of: - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide is also indicated for the prevention of: - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life threatening. use of flecainide for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in th

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of: •paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp,

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - flecainide acetate - tablet - 100 milligram(s) - antiarrhythmics, class ic; flecainide

United States - English - NLM (National Library of Medicine)

avkare, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician, are lifethreatening. use of flecainide for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - flecainide acetate - tablet - 50 milligram(s) - antiarrhythmics, class ic; flecainide